With reference to the email dated 17.05.2021, reference no. L/SURV/ONL/PV/NJ/ 2021-2022 / 69, seeking clarification in respect of increase in volume of the Company’s security across exchanges, in recent past. Hester Biosciences has informed that the Company has submitted a clarification /rejoinder for the news on Hester tying up with Gujarat Biotechnology Research Centre, Department of Science & Technology, Government of Gujarat and with Omnibrx towards manufacturing Covid vaccine on 15.05.2021 under the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has clarified that there is no pending information and/or announcements which in its opinion may have a bearing on the Price/Volume behaviour of the Company's securities traded across exchanges or which requires disclosures in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company understand that the movement in volume/ share price of the company is purely due to market conditions and absolutely market driven and the Company is in no way connected with any such movement in price/volume. The Company has been regularly making disclosures in case of any events/information/announcements that require disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’).
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: